Staphylococcus aureus biofilm as a target for single or repeated doses of oxacillin, vancomycin, linezolid and/or lysostaphin
Jazyk angličtina Země Spojené státy americké Médium print
Typ dokumentu hodnotící studie, časopisecké články, práce podpořená grantem
PubMed
17176756
DOI
10.1007/bf02931580
Knihovny.cz E-zdroje
- MeSH
- acetamidy farmakologie MeSH
- antibakteriální látky farmakologie MeSH
- biofilmy účinky léků růst a vývoj MeSH
- kombinovaná farmakoterapie MeSH
- konfokální mikroskopie MeSH
- lidé MeSH
- linezolid MeSH
- lysostafin farmakologie MeSH
- mikrobiální testy citlivosti MeSH
- oxacilin farmakologie MeSH
- oxazolidinony farmakologie MeSH
- stafylokokové infekce farmakoterapie MeSH
- Staphylococcus aureus účinky léků MeSH
- vankomycin farmakologie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- hodnotící studie MeSH
- práce podpořená grantem MeSH
- Názvy látek
- acetamidy MeSH
- antibakteriální látky MeSH
- linezolid MeSH
- lysostafin MeSH
- oxacilin MeSH
- oxazolidinony MeSH
- vankomycin MeSH
Due to high resistance, standard chemotherapy of biofilm-associated staphylococcal infections is ineffective and a number of alternative approaches to antimicrobial treatment have been proposed. Minimum inhibitory concentration (MIC) and biofilm inhibitory concentration (BIC) of oxacillin (Oxa), vancomycin (Van), linezolid (Lzd) and lysostaphin (Lss) as well as the possible synergistic effect of the antibiotics and lysostaphin were determined. The Lss susceptibility of Staphylococcus aureus planktonic and bio-film cultures varied and was strain-dependent. The synergistic effect of sub-BIC(Lss)+Oxa was observed for methicillin-sensitive S. aureus (MSSa) and methicillin-resistant S. aureus (MrSa), but not for heterogeneously vancomycin-resistant S. aureus (V(h)Sa) biofilm. Van with sub-BICL(Lss) was effective against M(s)Sa and MrSa biofilm, when applied in three subsequent doses. Only sub-BICL(Lss)+Lzd combination, given as three cycles therapy, was effective in disruption of all 3 (M(s)Sa, M(r)Sa, V(h)Sa) biofilms.
Zobrazit více v PubMed
J Antimicrob Chemother. 2001 Nov;48(5):617-25 PubMed
Pol J Microbiol. 2005;54(3):191-200 PubMed
Folia Microbiol (Praha). 2004;49(1):75-8 PubMed
Mol Microbiol. 2002 Mar;43(6):1367-78 PubMed
Antimicrob Agents Chemother. 2002 Feb;46(2):598-9 PubMed
Antimicrob Agents Chemother. 2001 Apr;45(4):999-1007 PubMed
Folia Microbiol (Praha). 2004;49(5):596-600 PubMed
Antimicrob Agents Chemother. 2001 May;45(5):1431-7 PubMed
J Antimicrob Chemother. 2003 May;51 Suppl 2:ii27-35 PubMed
J Microbiol Methods. 2003 Aug;54(2):269-76 PubMed
Antimicrob Agents Chemother. 2003 Nov;47(11):3407-14 PubMed
Vaccine. 1999 May 14;17 (19):2423-8 PubMed
J Antimicrob Chemother. 2002 Feb;49(2):301-8 PubMed
Antimicrob Agents Chemother. 2002 Jun;46(6):2017-20 PubMed
Nat Rev Microbiol. 2004 Feb;2(2):95-108 PubMed
Expert Rev Anti Infect Ther. 2003 Dec;1(4):667-83 PubMed
Invest Ophthalmol Vis Sci. 2002 Dec;43(12):3712-6 PubMed
Ann Clin Microbiol Antimicrob. 2005 Jan 07;4:2 PubMed
Antimicrob Agents Chemother. 2004 May;48(5):1681-7 PubMed
In vitro effects on biofilm viability and antibacterial and antiadherent activities of silymarin
Bacteria competing with the adhesion and biofilm formation by Staphylococcus aureus
Antibiotic synergy against biofilm-forming Pseudomonas aeruginosa
Staphylococcus cohnii hemolysins - isolation, purification and properties
Characteristics of Staphylococcus aureus isolated from rabbits
Ribotyping and biotyping of Staphylococcus epidermidis isolated from hospital environment
Treatment of orthopedic infections caused by resistant staphylococci